

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 019934-003800US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On SEPT 30, 2004



TOWNSEND and TOWNSEND and CREW LLP

By: Nicole Wartell  
Nicole Wartell

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Yu Wang et al.

Application No.: 10/773,380

Filed: February 6, 2004

For: CELL PROLIFERATION  
ASSOCIATED WITH CCX CKR  
EXPRESSION

Examiner: Not yet known

Art Unit: Not yet known

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. U.S. patents are not enclosed in accordance with the Patent Office waiver issued August 5, 2003 in the Official Gazette, which states as follows:

The Office hereby waives the requirement under 37 CFR 1.98

(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371

after June 30, 2003. See 37 CFR 1.491(b).

In accordance with 37 CFR 1.98(a)(2), copies of the foreign patents and non-patent literature references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:nmb  
60224091 v1



PTO/SB/21 (04-04)

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/773,380
Filing Date	February 6, 2004
First Named Inventor	Wang, Yu
Art Unit	Not yet known
Examiner Name	Not yet known
Attorney Docket Number	019934-003800US

Total Number of Pages in This Submission

**ENCLOSURES** (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, copies of forty-six (46) cited references
--	---	---

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	Townsend and Townsend and Crew LLP
Signature	Scott L. Aussenhus <i>Scott L. Aussenhus</i>
Date	09-29-04

Reg. No. 42,271


**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name  
Nicole M. WartellSignature  
*Nicole M. Wartell*

Date

9/30/2004



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/773,380	
			Filing Date	February 6, 2004	
			First Named Inventor	Wang, Yu	
			Art Unit	Not yet known	
			Examiner Name	Not yet known	
Sheet	1	of	4	Attorney Docket Number	019934-003800US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	A1	US-5,194,596	03-16-1993	Tischer et al.	
	A2	US-5,350,836	09-27-1994	Kopchick et al.	
	A3	US-5,932,445	08-03-1999	Lal et al.	
	A4	US-6,110,695	08-29-2000	Gunn et al.	
	A5	US-2001/0016336 A1	08-23-2001	Ellis	
	A6				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	EP	0 899 332	A2	03-03-1999	Smith Kline Beecham		<input type="checkbox"/>
	B2	PCT	WO 99/24463	A2	05-20-1999	Incyte Pharmaceuticals, Inc.		<input type="checkbox"/>
	B3	PCT	WO 99/33876	A1	07-08-1999	Asahi Kasei Kogyo Kabushiki		<input checked="" type="checkbox"/>
	B4	PCT	WO 99/52945	A2	10-21-1999	Millenium Pharmaceuticals, Inc.		<input type="checkbox"/>
	B5	PCT	WO 00/26369	A1	05-11-2000	Chiron Corporation		<input type="checkbox"/>
	B6	PCT	WO 00/64941	A2	11-02-2000	Curagen Corporation		<input type="checkbox"/>
	B7							<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
60224091 v1

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/773,380	
			Filing Date	February 6, 2004	
			First Named Inventor	Wang, Yu	
			Art Unit	Not yet known	
			Examiner Name	Not yet known	
Sheet	2	of	4	Attorney Docket Number	019934-003800US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	BAGGIOLINI, M. "Chemokines in pathology and medicine." Journal Internal Medicine, 2001, pp. 91-104, Vol. 250.	
	C2	BENJAMIN, LAURA et al. "A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF" Development, 1998, pp. 1591-1598, Vol. 125.	
	C3	BORK, PEER, et al; Go hunting in sequence databases but watch out for the traps; <i>Trends in Genetics</i> ; October 1996; pp. 425-427; Vol. 12, No. 10	
	C4	BORK, PEER; Powers and Pitfalls in Sequence Analysis: The 70% Hurdle; <i>Genome Research</i> ; 2000; pp. 398-400; Vol. 10	
	C5	BRENNER, Steven E. "Errors in genome annotation"; <i>Trends in Genetics</i> ; April 1999; pp. 132-133; Vol. 15, No. 4	
	C6	CREIGHTON, T.E. (editor), Protein structure a practical approach, 1990, pages 184-185, Information Press Ltd., Oxford, England.	
	C7	DAIRAGHI, DANIEL J. et al.; HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8; The Journal of Biological Chemistry; July 30, 1999; pp. 21569-21574; Volume 274, No. 31	
	C8	DAIRAGHI, DANIEL J.; et al. Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength; The Journal of Biological Chemistry; November 7, 1997; pp. 28206-28209; Volume 272, No. 45	
	C9	DATABASE EMBL Accession No. Q9NPB9; 1 October 2000	
	C10	DATABASE EMBL Accession No. Y30125; 14 October 1999	
	C11	DOERKS, TOBIAS, et al.; Protein annotation: detective work for function prediction; <i>Trends in Genetics</i> ; June 1998; pp. 248-250; Vol. 14, No. 6	
	C12	GenBank Accession Number AA215577; August 13, 1997	
	C13	GenBank Accession Number AF233281; May 22, 2000	
	C14	GenBank Accession Number AI131555; October 26, 1998	
	C15	GenBank Accession Number AI769466; June 28, 1999	
	C16	GenBank Accession Number AR003970; December 10, 1998	
	C17	GenBank Accession Number AW190975; November 22, 1999	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/773,380	
			Filing Date	February 6, 2004	
			First Named Inventor	Wang, Yu	
			Art Unit	Not yet known	
			Examiner Name	Not yet known	
Sheet	3	of	4	Attorney Docket Number	019934-003800US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C18	GenBank Accession Number E12852; June 24, 1998	
	C19	GenBank Accession Number H67224; October 27, 1995	
	C20	GOSLING, JENNIFA, et al; Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell-and T Cell-Active Chemokines Including ELC, SLC, and TECK; The Journal of Immunology; 2000; pp. 2851-2856	
	C21	HULME, E.C., editor; Receptor-Ligand Interactions A Practical Approach; 1992; Preface, Table of Contents, Chapters 6,7, 8 and 9; pp. viii-xv and 213-263; IRL Press at Oxford University Press Inc., New York, New York	
	C22	KHOJA, HAMIDUDDIN, et al. "Cloning of CCRL1, an orphan seven transmembrane receptor related to chemokine receptors, expressed abundantly in the heart"; Gene; 2000; pp. 229-238; Volume 246	
	C23	MASSAGUE, JOAN "The TGF- $\beta$ Family of Growth and Differentiation Factors" Cell, May 22, 1987, pp. 437-438, Vol. 49.	
	C24	MATSUOKA, ICHIRO et al.; Identification of Novel Members of G-Protein Coupled Receptor Superfamily Expressed in Bovine Taste Tissue; Biochemical and Biophysical Research Communications; July 15, 1993; pp. 504-511; volume 194, No. 1	
	C25	MURDOCH, CRAIG & FINN, ADAM "Chemokine receptors and their role in inflammation and infectious diseases" Blood, May 15, 2000, pp. 3032-3043, Vol. 95, No. 10.	
	C26	MURPHY, P. "International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature" Pharmacological Reviews, 2002, pp. 227-229, Vol. 54, USA.	
	C27	NGO, J. THOMAS, et al; Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox; <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , K. Merz, Jr. and S. LeGrand, Editors; 1994; pp. 491-495; Birkhauser, Boston	
	C28	O'DOWD, BRIAN F., et al.; A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain; FEBS Letters 1996; pp 325-329	
	C29	PILBEAM, C.C. et al. "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture" Bone, 1993, pp. 717-720, Vol. 14.	
	C30	SCHWEICKART, VICKI L. et al.; CCR11 Is a Functional Receptor for the Monocyte Chemoattractant Protein Family of Chemokines; The Journal of Biological Chemistry; March 31, 2000; pp. 9550-9556; volume 275, No. 13.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/773,380	
			Filing Date	February 6, 2004	
			First Named Inventor	Wang, Yu	
			Art Unit	Not yet known	
			Examiner Name	Not yet known	
Sheet	4	of	4	Attorney Docket Number	019934-003800US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C31	SISSORS, DANIEL L., et al.; A Homogeneous Receptor Binding Assay for HTS on FlashPlate® Plus; NEN® Life Science Products, Inc.; 1999; pp. 1-7	
	C32	SKOLNICK, JEFFREY, et al; From gene to protein structure and function: novel applications of computational approaches in the genomic era; <i>Trends in Biotech</i> ; 2000; pp. 34-39; Vol. 18, No. 1	
	C33	SMITH, TEMPLE F., et al; The challenges of genome sequence annotation or "The devil is in the details"; <i>Nature Biotechnology</i> ; November 1997; pp. 1222-1223; Vol. 15	
	C34	TOWNSON, JANE R., et al.; "Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3β/mCCL19: comparison to human CCX-CKR" <i>Eur. J. Immunol</i> ; 2002; pp. 1230-1241; Volume 32	
	C35	VUKICEVIC, SLOBODAN et al. "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)" <i>Proc. Natl. Acad. Sci., USA</i> , August 1996, pp. 9021-9026, Vol. 93	
	C36	WELLS, JAMES A.; Additivity of Mutational Effects in Proteins; <i>Biochemistry</i> ; September 18, 1990; pp. 8509-8517; Vol. Vol. 29, No. 37	
	C37	YOSHIDA, RYU et al., Molecular Cloning of a Novel Human CC Chemokine EBI1-ligand Chemokine That is a Specific Functional Ligand for EBI1, CCR7, <i>The Journal of Biological Chemistry</i> , May 23, 1997, pages 13803-13809, Vol. 272, No. 21.	
	C38	YOSHIDA, RYU et al., Secondary Lymphoid-tissue Chemokine Is a Functional Ligand for the CC Chemokine Receptor CCR7, <i>The Journal of Biological Chemistry</i> , March 20, 1998, pages 7118-7122, Vol. 273, No. 12.	
	C39	YOUN, BYUNG-S. et al., TECK, an Efficacious Chemoattractant for Human Thymocytes, Uses GPR-9-6/CCR9 as a Specific Receptor, <i>Blood</i> , October 1, 1997, pages 2533-2536, Vol. 94, No. 7.	
	C40	Zaballos, Angel et al., Cutting Edge: Identification of the Orphan Chemokine Receptor GPR-9-6 as CCR9, the Receptor for the Chemokine TECK, <i>The Journal of Immunology</i> , 1999, pages 5671-5675.	
	C41		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.